Choosing the right therapy for kidney failure may be difficult. Become familiar with the therapy options and, together with your physician, choose the therapy that best suits your health status and lifestyle.
The dialysis therapy you chose is not set in stone. Your personal lifestyle and changing medical factors also play a role in your choice of therapy. Those factors may change during your life or there might be complications which require switching to another form of treatment. Many patients do not undergo just one form of treatment in their lifetimes.
Each therapy option has its own advantages and disadvantages and not every therapy is suitable for every patient, which may limit your choices. Together with your physician and your family, you can decide which therapy is best for you in terms of treatment results and your individual quality of life.
The donor kidney is inserted into the lower parts of the abdomen. The diseased kidneys are usually not removed, mainly so patients benefit from the remaining functions of the kidney. If all goes well (i.e. the surgery is successful and appropriate medication to keep the kidney within the body and prevent rejection), the new kidney takes over the tasks of the diseased kidneys enough to partially restore the lost kidney function. A successfully transplanted kidney can work for many years. If the transplant is not successful, dialysis is still an option. Many patients with kidney disease go through different treatment modalities during their lifetimes (e.g. starting with peritoneal dialysis, then a having kidney transplant, then switching to haemodialysis after the donor kidney may lose function or complications occur), so a failed transplant is not the last option.
A successful transplant can help the patient to achieve a better state of health without dialysis. To prevent rejection of the donor kidney, the patient (recipient) must take regular medications during and/or after the transplant. These medications are generally referred to as immunosuppressives.
Since your immune system will be weaker compared to that of others, you should be aware of the potential complications of immunosupressive therapy i.e. risk of developing infections. Therefore, it is essential to follow advice given by your healthcare team. These medications can cause side effects, which may vary depending on the type of immunosupressants. You will be monitored for these, and given advice on how to look out for some of these complications. For patients with a donor kidney, it is important that the anti-rejection and other medication is taken daily and that regular follow-up examinations take place.
Peritoneal Dialysis (PD) is named after the peritoneum. This is a thin, velvety tissue that lines the abdominal cavity and the internal organs. It is naturally present in every person’s body. This form of dialysis uses the peritoneum as a natural filter to replace kidney function. To do so, a fresh dialysis solution is introduced into the abdomen via a soft tube called a catheter that is surgically inserted into your abdomen. Depending on your physician’s prescription, it remains there for a few hours and is replaced as soon as toxins and excess body water have been absorbed.
PD is performed either as Continuous Ambulatory Peritoneal Dialysis (CAPD) (manually) or as Automated Peritoneal Dialysis (APD) (using a machine). In rare cases, a combination of two types can also be used. PD treatment is performed by filling the abdomen with dialysate (these are called exchanges), allowing the dialysate to remain for a prescribed dwell time, then draining the waste fluid from the abdomen. Excellent standards of hygiene are mandatory for PD treatment to avoid risk of infection and you must take great care to protect your exit site. There is time whilst on PD treatment for you to participate in seated activities such as reading a book. You will receive extensive training from your care team before performing dialysis on your own, all necessary steps will be communicated during training. The decision to use one of the two PD options depends on your lifestyle, health condition and personal preferences and is made together in consultation with your physician. You may find it helpful to involve relatives or other patients in your decision. Everything can be done together!
After applying hygiene measures, you connect the set of CAPD plastic bags filled with dialysis solution to your catheter. The CAPD set typically consists of two bags, one empty waste bag and one bag filled with 2-2.5 litres of cleansing fluid, or dialysis solution. You drain the used dialysis solution through your catheter, which takes about 20 minutes. After draining the used fluids, flush the catheter with a small amount of fresh dialysate.
Now you can fill your abdominal cavity with the fresh dialysis solution. After hanging the plastic bag on the infusion pole at shoulder level, gravity pulls the fluid into your abdomen. This process is called filling and takes about 10 minutes. You can then disconnect the set and cap your catheter.
The whole process, which consists of the three steps - filling, dwelling and draining - is called a bag exchange. This process takes about 30 minutes and is typically done three to five times a day. Some patients prefer to do the bag exchanges before or after mealtime or at bedtime. All the necessary steps are taught and explained to you in advance during a training session.
The dialysis solution remains in your abdominal cavity for several hours. This is called dwelling. During this dwell time, which is the time between two exchanges, waste products and extra fluid are removed from your blood through the peritoneum into the dialysis solution, which is removed from the body at the next bag exchange.
Additional mental health benefits of frequent HHD have been described. A short, daily haemodialysis session has been shown to improve mental health and lead to fewer depression episodes.
Moreover, if you are working, there may be more flexibility, as the dialysis time is shorter.
Lastly, sleeping disturbances and restlessness in your legs may be lessened.
All those benefits may have a big impact on a patient’s individual situation and well-being. As a result, frequent HHD could be a treatment option. Please talk to your dialysis team if this may also be an option for you as well.
HHD is proposed as a preferable choice for patients who want to continue to work, stay as flexible as possible and perform dialysis in a familiar environment.
If you choose in-centre dialysis, you usually have three fixed appointments per week, typically for a four-hour treatment in your dialysis centre. With this treatment option, in general, the dialysis team will prepare, carry out and monitor the dialysis for you.
Depending on your (medical) conditions, dialysis might not prolong or improve the quality of your life and the best option might be to let nature take its course. Regardless of medical conditions, based on individual situations and preferences, some patients decide not to start or also discontinue renal replacement therapy.
You have the option of not receiving renal replacement treatment and life-prolonging treatment at all. The kidney function will then not be replaced and your kidneys will fail, resulting in natural death. Your health care team will still support you and treat your symptoms with medication and, if necessary, give supportive forms of nutrition. Conservative therapy is more about maintaining quality of life.
Your health team will talk with you to help you make an informed and considered decision.
Keeping and going to your appointments and following your treatment plan is critical to your health. Therefore, it is important to choose a therapy that suits your personal situation. Always remember: The return for the time you invest can be a fuller, more active and healthier life.
You have now learned an overview of what treatment options are available. Together with your medical team, you can discuss and decide which of those treatment options would be the most suitable for you.
Read more about making the right decision in the next section.
Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment [Dir 2001/20/EC Art 2(m)].
An adverse event can therefore be any unfavourable and unintended sign (e.g. an abnormal laboratory finding), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product (Annex 4 Guideline on good pharmacovigilance practices (GVP) Rev 4).
If you get any side effects, talk to your Doctor, Pharmacist or Nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side effects, you can help provide more information on the safety of this medicine.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Fresenius Medical Care on 01623 445 215 and via medinfo-uk@freseniusmedicalcare.com
Call 01623 445 100 (please choose option 5). Opening times are Monday - Friday 9am - 5pm.
UK/HEMA/FME/0922/0002 – Date of Preparation September 2022.
1 Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. 1998;53(5):1399-1404. doi:10.1046/j.1523-1755.1998.00875.x
2 Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007;298(11):1291-1299. doi:10.1001/jama.298.11.1291
3 Chan CT, Shen SX, Picton P, Floras J. Nocturnal home hemodialysis improved baroreflex effectiveness index of end-stagerenal disease patients. J Hypertens. 2008; 26(9):1795-1800. doi: 10.1097/HJH.0b013e328308b7c8
4 Marshall MR, Polkinghorne KR, Kerr PG, Hawley CM, Agar JW, McDonald SP. Intensive Hemodialysis and Mortality Risk in Australian and New Zealand Populations. Am J Kidney Dis. 2016;67(4):617-628. doi:10.1053/j.ajkd.2015.09.025
5 Rydell H, Ivarsson K, Almquist M, Segelmark M, Clyne N. Improved long-term survival with home hemodialysis compared with institutional hemodialysis and peritoneal dialysis: a matched cohort study. BMC Nephrol. 2019;20(1):52.
Published 2019 Feb 13. doi:10.1186/s12882-019-1245-x
6 Marshall MR, Walker RC, Polkinghorne KR, Lynn KL. Survival on home dialysis in New Zealand. PLoS One. 2014;9(5):e96847. Published 2014 May 7. doi:10.1371/ journal.pone.0096847